en · de · es · fr · pt
analytical-notes.peptides6823.com › Faq › Receptor Action And Pharmacokinetics — Quick Reference

Receptor Action And Pharmacokinetics — Quick Reference

By Editorial Desk · published 2025-08-15 · last reviewed 2025-09-15 · Faq

If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Related pages on this site

Handling Storage and Quality Control

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Supporting material

Trump stated that if he were elected, he would increase deportations, send the U.S. military to the border, expand U.S. Immigration and Customs Enforcement detentions through workplace raids, deputize local law enforcement to handle border security, increase U.S. Customs and Border Protection funding, as well as finish building the wall on the southern border. Trump has said he will deport both legal and illegal immigrants. The New York Times reported that Trump was considering "an extreme expansion of his first-term crackdown on immigration", such as "preparing to round up undocumented people already in the United States on a vast scale and detain them in sprawling camps while they wait to be expelled". Trump stated his intention to deport 11 million people through the construction of detention camps and deploy the military, relying on presidential wartime powers under the 18th-century Alien Enemies Act. Trump made false claims of a "migrant crime wave" that are not supported by data, and provided no evidence to back up his claims. In regards to his anti-immigrant nativism, Trump's tone grew harsher from his previous time as president, and used fearmongering, racial stereotypes, and more dehumanizing rhetoric when referring to illegal immigrants.

glycogen(n residues) + Pi ⇌ glycogen(n-1 residues) + glucose-1-phosphate Here, glycogen phosphorylase cleaves the bond linking a terminal glucose residue to a glycogen branch by substitution of a phosphoryl group for the α[1→4] linkage. Glucose-1-phosphate is converted to glucose-6-phosphate (which often ends up in glycolysis) by the enzyme phosphoglucomutase. Glucose residues are phosphorolysed from branches of glycogen until four residues before a glucose that is branched with a α[1→6] linkage. Glycogen debranching enzyme then transfers three of the remaining four glucose units to the end of another glycogen branch. This exposes the α[1→6] branching point, which is hydrolysed by α[1→6] glucosidase, removing the final glucose residue of the branch as a molecule of glucose and eliminating the branch. This is the only case in which a glycogen metabolite is not glucose-1-phosphate. The glucose is subsequently phosphorylated to glucose-6-phosphate by hexokinase.

=== Neurosurgical repair === Surgery to treat a CSF-venous fistula in CSF leak patients is highly effective. Neurosurgery is available to directly repair leaking meningeal diverticula. The areas of dura leak can be tied together in a process called ligation and then a metal clip can be placed in order to hold the ligation closed. Alternatively, a small compress called a pledget can be placed over the dura leak and then sealed with gel foam and fibrin glue. Primary suturing is rarely able to repair a CSF leak, and in some patients exploration of the dura may be required to properly locate all sites of CSF leak.

Sources: en.wikipedia.org

Notes from published material

=== Pregnancy === Paracetamol has long been established as a safe medication to treat short-term fever and significant pain in pregnant patients. Regulatory agencies, including the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), the World Health Organization (WHO), and the U.S. Food and Drug Administration (FDA) recommend paracetamol as a first-line analgesic and antipyretic in pregnancy, with use limited to situations where necessary, at the lowest effective dose, and for the shortest duration. Some observational studies have suggested a possible association between prenatal paracetamol use and neurodevelopmental disorders, including ADHD and autism. However, these studies are limited by confounding factors such as maternal fever and infection, and do not demonstrate causation. Large, well-controlled studies, including sibling-controlled analyses, find no causal link after adjusting for maternal conditions. In support of existing recommendations for its safe use during pregnancy, a 2026 review found that there were no clinically significant increases in the occurrence of autism, attention deficit hyperactivity disorder, or intellectual disability in the children of pregnant women who used paracetamol as directed. Untreated pain and fever can harm mother and fetus.

=== First complete genomic nucleotide sequence === The 3569-nucleotide sequence of all of the genes of the RNA bacteriophage MS2 was determined by a large team of researchers over several years, and was reported in a series of scientific papers. These results enabled the analysis of the first complete genome, albeit an extremely tiny one by modern standards. Several surprising features were identified, including genes that partially overlap one another and the first clues that different organisms might have slightly different codon usage patterns.

The Appalachian Uplands are one of the seven physiographic divisions in Canada. Canada's GSC does not use the same classification system as the USGS below the division level. The agency does break the divisions of the Appalachian Uplands into 13 subsections that are in four different political provinces of Canada.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network